BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lowenstern A, Al-Khatib SM, Sharan L, Chatterjee R, Allen LaPointe NM, Shah B, Borre ED, Raitz G, Goode A, Yapa R, Davis JK, Lallinger K, Schmidt R, Kosinski AS, Sanders GD. Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation: A Systematic Review. Ann Intern Med 2018;169:774-87. [PMID: 30383133 DOI: 10.7326/M18-1523] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Deitelzweig S, Bergrath E, di Fusco M, Kang A, Savone M, Cappelleri JC, Russ C, Betts M, Cichewicz A, Schaible K, Tarpey J, Fahrbach K. Real-world evidence comparing oral anticoagulants in non-valvular atrial fibrillation: a systematic review and network meta-analysis. Future Cardiol 2022. [PMID: 35360925 DOI: 10.2217/fca-2021-0120] [Reference Citation Analysis]
2 Ray WA, Chung CP, Stein CM, Smalley W, Zimmerman E, Dupont WD, Hung AM, Daugherty JR, Dickson A, Murray KT. Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation. JAMA 2021;326:2395-404. [PMID: 34932078 DOI: 10.1001/jama.2021.21222] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
3 Sinyavskaya L, Schnitzer M, Renoux C, Guertin JR, Talbot D, Durand M. Evidence of the Different Associations of Prognostic Factors With Censoring Across Treatment Groups and Impact on Censoring Weight Model Specification: The Example of Anticoagulation in Atrial Fibrillation. Am J Epidemiol 2021;190:2671-9. [PMID: 34165152 DOI: 10.1093/aje/kwab186] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Neumann I, Schünemann HJ, Bero L, Cooke G, Magrini N, Moja L. Global access to affordable direct oral anticoagulants. Bull World Health Organ 2021;99:653-60. [PMID: 34475602 DOI: 10.2471/BLT.20.278473] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 van Uden RCAE, van den Broek MPH, Houtenbos I, Jaspers TCC, Harmsze AM, Kingma HJ, Odekerken DAM, Meijer K, van den Bemt PMLA, Becker ML. Unintentional guideline deviations in hospitalized patients with two or more antithrombotic agents: an intervention study. Eur J Clin Pharmacol 2021. [PMID: 34319470 DOI: 10.1007/s00228-021-03185-y] [Reference Citation Analysis]
6 Esmaeili S, Abolmaali M, Aarabi S, Motamed MR, Chaibakhsh S, Joghataei MT, Mojtahed M, Mirzaasgari Z. Rivaroxaban for the treatment of cerebral venous thrombosis. BMC Neurol 2021;21:73. [PMID: 33588777 DOI: 10.1186/s12883-021-02091-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Durand M, Schnitzer ME, Pang M, Carney G, Eltonsy S, Filion KB, Fisher A, Jun M, Kuo IF, Renoux C, Paterson JM, Quail J, Matteau A; Canadian Network for Observational Drug Effect Studies Investigators. Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study. CMAJ Open 2020;8:E877-86. [PMID: 33355273 DOI: 10.9778/cmajo.20200055] [Reference Citation Analysis]
8 Kampouraki E, Abohelaika S, Avery P, Biss T, Murphy P, Wynne H, Kamali F. Elderly people are inherently sensitive to the pharmacological activity of rivaroxaban: implications for DOAC prescribing. J Thromb Thrombolysis 2021;52:170-8. [PMID: 33131001 DOI: 10.1007/s11239-020-02326-x] [Reference Citation Analysis]